• Renewed health in the oil and gas sectors show an ongoing need for products such as Petroteq Energy’s closed-loop, clean surface extraction CORT operation
• Petroteq is developing what it believes to be the next big thing in the industry after fracking generated a domestic oil production boom in the United States
• While performing maintenance and upgrades at its Utah production site, Petroteq continues to demonstrate its technology’s potential through licensing and lab testing

A new year of continuing recovery in the oil and gas markets has industry watchers enthused about the outlook for U.S. productivity for domestic and international consumers during the coming decades, with production currently hovering at a level of 19-20 million barrels per day. Demand for U.S. oil is “buoyantly very high,” with more than 2.5 million barrels per day of crude oil exported in April, according to Forbes (http://ibn.fm/4BG8v), at a rate that was 35 percent higher than the previous April. Oil product exports, on the other hand, were double that amount.

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is building momentum as an innovator of CORT (Clean Oil Recovery Technology) and is making surface tar sands oil extraction cleaner and simpler than ever. Through a closed-loop recovery process conducted at ground level, Petroteq is removing bituminous oils from the tar sands that are plentiful in Utah’s rural eastern desert and leaving behind sands that are clean enough to grow produce.

CEO David Sealock showcased the operations processes of the company’s two-year labor of love at Utah’s Asphalt Ridge in a video tour of Petroteq’s facilities published in June (http://ibn.fm/qnZwt) in celebration of phase I production.

The company halted operations in order to perform planned equipment re-engineering. The coarseness of the Utah desert sands interfered with initial efforts to arrive at an earlier deadline, but the maintenance alterations to the equipment are expected to decrease the costs of further maintenance in the future and improve the facility’s efficiency in reaching its production goals.

While the facility upgrade advances toward recommencement of production, Petroteq has been pressing the advantages of its technology with other companies in the United States and abroad, approving its first non-exclusive licensing agreement with eastern Texas energy services company Valkor LLC in July and completing demonstrative lab projects for Asian and Australian interests that show the ability of Petroteq’s technology in recovering oil from tar sands and shale (http://ibn.fm/UDwtL).

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018
• Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities
• The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent
• Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016
• Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery, reducing the need for pain medications that can lead to addiction
• The company’s proprietary wearable device can be used for a wide range of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue

Finding answers to the nation’s opioid epidemic is a complex problem being fought on several fronts. In a news release, Alan Collier, chief executive officer of Endonovo Therapeutics Inc. (OTCQB: ENDV), stated that the company’s SofPulse post-operative opioid alternative medical device delivers clinically-proven post-surgical pain relief to patients.

“With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis,” Collier noted (http://ibn.fm/ksEeK).

Federal statistics show that opioids kill more people per year than car crashes on America’s roadways. An estimated 68,000 Americans died from a drug overdose stemming from opioid abuse in the United States in 2018, although that number could rise once final numbers are compiled, according to Centers for Disease Control and Prevention (CDC) reports (http://ibn.fm/Kd4TZ).

The CDC reported that, in 2016, 11.5 million people misused opioids (http://ibn.fm/NY2Dh), while the Department of Justice reports that four out of five heroin users first misused prescription opioids (http://ibn.fm/meham).

Drug overdose deaths involving any opioid rose from 18,515 deaths in 2007 to 47,600 in 2017, with 68 percent of those deaths occurring among men, per CDC data. In addition, the National Safety Council reports that impaired driving caused by drugs, including opioids, contributed to some of the 40,000 fatal crashes that occurred in each of the past three years (http://ibn.fm/gqf93).

Endonovo’s SofPulse provides targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue. Endonovo’s SofPulse is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving patients’ natural recovery experiences (http://ibn.fm/BxHsd).

Endonovo’s Electroceutical Therapy(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical Therapy represents “a fascinating new frontier.” Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist.

“Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” Novak stated in a news release (http://ibn.fm/RPZRt). “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• The hemp-derived CBD market is projected to reach $22 billion by 2022
• The company recently entered into a tolling agreement to process five million kilograms of hemp biomass
• HTC has entered into an agreement with Canaccord Genuity Corp. for a C$15 million bought deal private placement

With the passage of the Agriculture Improvement Act of 2018 (commonly known as the 2018 farm bill), hemp production and distribution in the United States became permissible under federal law. Freed from its legal shackles, the industry is experiencing rapid growth. As production and distribution of hemp increases, the business of extracting CBD from hemp biomass, as opposed to extraction from marijuana, is looking more feasible, so much so that industry analyst Brightfield Group projects that the hemp-derived CBD (cannabidiol) market will grow to $22 billion by 2022 (http://ibn.fm/xD28h). This market expansion is already increasing demand for extraction technology such as the Delta Purification System provided by HTC Extraction Systems (TSX.V: HTC). The company has inked one agreement and is in negotiations with other biomass providers in Canada and the United States.

HTC’s proprietary biomass processing occurs in three phases: pre-oil preparation, oil extraction and oil refinement. During the pre-oil extraction stage, the hemp is pulverized and dried. The resulting biomass is then immersed in ethanol, and the resulting mixture – containing cannabinoids, oils, ethanol and plant liquids – is separated from the plant fibers. During the last phase, the oil is collected, with 90 percent of the ethanol being removed and recycled, resulting in an approximate 50 percent CBD crude oil. The crude is then subjected to further distillation to achieve full spectrum oil (FSO) and/or pure CBD isolate.

HTC recently announced its entry into a hemp biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://ibn.fm/hjw4g). The agreement covers 4,200-5,000 acres of hemp in Saskatchewan, utilizing five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process an estimated five million kilograms of hemp biomass to extract CBD full-spectrum oil (FSO). The company will be paid a “toll fee,” or a percentage of the extracted CBD FSO distillate, for its processing, extraction, purification and distillation services. Toll fees are payments made to companies that provide specialized manufacturing or processing services.

Additionally, HTC is in negotiations with a large hemp biomass producer that has some 60,000 acres of hemp under cultivation. The company intends to enter into a tolling contract with this producer for production crop years 2019, 2020, 2021 and beyond. Hemp biomass tolling contracts with producers are also being negotiated in the United States for the 2020 hemp-crop growing year, under which HTC will provide local-to-grower, drying-to-biomass storage capability and transportation of dried biomass to an HTC extraction facility.

HTC boosted its capital in 2019 by entering into a letter agreement, with Canaccord Genuity Corp. acting as sole book runner and lead underwriter on behalf of a syndicate of underwriters that have agreed to purchase, subject to completion of due diligence, on a bought-deal, private-placement basis, 15 million units of the company’s common shares, at a price of C$1 per unit for aggregate gross proceeds of C$15 million (http://ibn.fm/ZTiVq).

With such endorsements, HTC seems set to capitalize on the mushrooming hemp biomass extraction business.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• A rapidly aging population and technological advances are contributing to the fast growth of the global pain management device market
• The market is currently dominated by neurostimulation devices, which accounted for half the revenue reported in 2018 – a trend that’s likely to continue over the next few years
• Endonovo Therapeutics is already establishing a leading position in the niche; the company’s SofPulse(R) pain management device has been rolled out in a national network of hospitals, clinics and pain management centers for thorough evaluation

The global pain management device market is anticipated to grow rapidly through 2026, expanding at a CAGR of 13.8 percent to reach $14.55 billion, according to Grand View Research’s recent ‘Pain Management Devices Market Size, Share & Trends Analysis Report’ (http://ibn.fm/0WD5t).

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical Therapeutic devices that target patient pain and inflammation while supporting wound recovery, has already developed its proprietary bioelectronics pain management device called SofPulse. The FDA-cleared device is proven to decrease pain by reducing swelling (edema) to address multiple medical conditions and help the recovery of patients after surgery.

Several factors will contribute to the sustainable growth of the global pain management device market, such as the rapidly aging population worldwide and the fact that a growing part of the population has started showing a preference for pain management devices over oral drugs administered in the aftermath of a surgical intervention.

Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50 percent of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period.

Recently, Endonovo announced the rollout of SofPulse in hospital and medical centers across the U.S. The company plans to be in the evaluation stage with 600 hospitals within the next 18 months. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Endonovo CEO Alan Collier said in a news release.

The public is demanding pain management options that offer an alternative to opioids. According to a recent Washington Post article (http://ibn.fm/hWkZ6), “Forty-eight states plus around 2,000 local and tribal governments have sued companies in the drug industry, arguing those that make, distribute and sell the drugs are partly responsible for a crisis that has killed more than 400,000 people across the country since 2000, according to the U.S. Centers for Disease Control and Prevention.” However, Collier emphasizes that there are currently very few products that can meet the demand. SofPulse is thus positioned to offer a safe and reliable pain management alternative.

The device works by delivering targeted pulse electromagnetic therapy. Targeted microcurrents deliver gentle pulses to affected tissues, reducing post-surgical pain and decreasing the need for the administration of pharmaceuticals by 2.2 times.

Endonovo’s proprietary technology is an effective treatment for inflammatory conditions, cardiovascular diseases and central nervous system disorders. The device has Federal Drug Administration (FDA) clearance for the treatment of post-surgical pain and edema and has also received CE marking in Europe for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at  http://ibn.fm/ENDV

• The Green Organic Dutchman is a cannabis-focused research and development company
• The company recently completed its inaugural shipment to the Ontario Cannabis Store, marking its entry into the recreational cannabis market
• TGOD continues to explore strategic worldwide opportunities

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is a leading producer of premium, certified-organic cannabis. Licensed to cultivate medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), the company produces organic medical cannabis in small batches using all-natural, organic, craft-growing principles. TGOD recently entered into the recreational cannabis market, where consumers are seeking a premium organic product.

With head offices in Mississauga, Ontario, TGOD has a planned capacity of 219,000 kilograms and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. TGOD cultivates its cannabis in a proprietary living soil, without irradiation and in accordance with all-natural principles. The company’s growing process has earned organic certification from Pro-Cert and ECOCERT, both of which are leading organic certification organizations (http://ibn.fm/ZS9Ui).

TGOD’s hybrid facilities offer key advantages over outdoor, indoor and greenhouse facilities. Those advantages include advanced humidity, temperature and overall environmental controls relative to traditional greenhouses. Advantages also include highly automated and positive-pressure rooms that lessen the chance of contaminants.

TGOD recently completed its inaugural shipment to the Ontario Cannabis Store, officially marking the company’s entrance into Canada’s recreational market. In today’s increasingly competitive cannabis market, consumers are developing distinct preferences, especially for organic products. A recent study indicated that over 50 percent of consumers are looking for their cannabis to be organic (http://ibn.fm/MahYL), and Ontario consumers are now able to experience TGOD’s acclaimed Unite Organic dried flower. The company’s high-THC (tetrahydrocannabinol) signature strain is available on www.OCS.ca and at select retail locations across the province of Ontario (http://ibn.fm/IoeTF).

“We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers,” TGOD CEO Brian Athaide stated in a news release. “Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients. Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply.”

In addition, TGOD continues to provide its products to its medicinal patients throughout Canada. TGOD products were initially available only to a small group of medical patients known as the Grower’s Circle. Subsequently, the company also signed supply agreements with the provinces of Alberta and British Columbia.

Growing to scale, TGOD has unique partnerships in place. The company’s partners include international power-management company Eaton Corp., which provides research and optimization that will enable TGOD to have some of the lowest electricity input costs in the business. This is an essential step in the company’s plan to become one of the lowest-cost producers in Canada. Eaton designed TGOD’s power-management system, and TGOD purchases its power from HCE Energy, owned by the city of Hamilton, Ontario. TGOD utilizes Hydro-Quebec in Valleyfield. The company has another key partnership with construction-management firm Ledcor. The focus of this partnership is on ensuring logistical and infrastructure controls. Ledcor specializes in project and construction management, preconstruction services, design-build and general contracting. TGOD’s alliance partners, which also include Neptune, Mediakos and Symrise AG, are industry leaders, enabling the company to achieve its energy and production goals.

TGOD continues to focus on becoming the largest organic cannabis company in the world. By taking advantage of innovative technology and low-cost power solutions, the company offers investors the potential for substantial ROI. With its proven management team, TGOD is positioned for continued expansion and sales across North America, Latin America and Europe, especially considering its recent entry into the recreational cannabis market

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Organigram’s corporate governance distinguishes the company in the cannabis industry
• OGI’s consistent financial performance positions it as an “anomaly in the Canadian cannabis market”
• The company recently upgraded from the TSX Venture Exchange to the Toronto Stock Exchange

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian licensed producer (LP) of premium-quality cannabis and extract-based products, is focused on producing high-quality, indoor-grown cannabis for patients and adult-recreational consumers. Championing that cause is Organigram’s leadership team, a group of seasoned professionals on the forefront of the global cannabis market who bring decades of experience in consumer-packaged goods, and pharma, including a CEO who held the same position at Tilray (NASDAQ: TLRY) before joining Organigram. In addition, the company’s fiscal discipline and execution, as well as its solid corporate governance foundation, distinguish it while some other LPs have met mild to severe consequences for regulatory breaches.

Bloomberg noted that OGI has a fully independent board of directors (excluding CEO Greg Engel), which is a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company. “This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards,” Engel told Bloomberg (http://ibn.fm/paDcr). “I think some of the challenges we’ve seen in the industry have been because of a lack of governance. You have to have independent governance that has oversight and holds management accountable.”

Along with the company’s impressive corporate governance comes its equally notable — and consistent — financial performance. This is likely due to its team’s adherence to fiscal discipline, something that can be difficult to find in this industry. Bloomberg noted that, with four quarters of profitability under its belt, Organigram Holdings is “an anomaly in the Canadian cannabis market.”

“Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production,” the report stated. “Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines. No other large Canadian pot producer has managed to post such a long string of positive EBITDA.”

In addition, the company recently uplisted to the Toronto Stock Exchange (TSX) from the TSX Venture Exchange (TSX.V) under the symbol ‘OGI’.

“Graduating to the TSX is a significant milestone for us as a corporation,” Engel stated in a news release (http://ibn.fm/g63Gj). “Our stakeholders have an eye on this marketplace, and this graduation will broaden our reach within the investment community and encourage new investors to learn more about our business, our growth plans and corporate objectives.”

As a result of many of these developments, OGI has attracted significant attention. OGI was deemed a “compelling cannabis stock to buy in August” in a recent article distributed by The Motley Fool (http://ibn.fm/3jeGk). “I continue to view the long-term prospects for Organigram in a favorable light,” contributor Keith Speights wrote. “Other Canadian cannabis producers get a lot more hype right now, but Organigram could be a rising star that will attract plenty of attention in the near future. What I really like about Organigram is that its management team exercises fiscal discipline, which is kind of a rarity in the industry.”

Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). Organigram has sales in all 10 Canadian provinces. The company has developed a portfolio of legal, adult-use recreational cannabis brands, including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Additionally, it delivers industry-leading yields and maximizes quality-cannabis production at one of the lowest cultivation costs per gram* among publicly reporting Canadian LPs. Organigram is committed to translating operational excellence into strong financial results and return on investment for shareholders.

* Cultivation cost per gram is a non-IFRS measure. Please see the Company’s latest MD&A.

For more information, visit the company’s website at www.Investors.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• HTC Extraction Systems is an experienced and successful gas, liquids and biomass extractor and refiner using patented technologies for extraction and distillation processes
• HTC is building a 19,000-square-foot GMP Euro-compliant extraction, purification and distillation facility in Saskatchewan, and it is scouting to build another in the United States for hemp extraction services
• The company recently announced a common shares bought deal, whereby, subject to closing, $15 million in aggregate gross proceeds will be added to its bottom line

Extraction and distillation technology developer HTC Extraction Systems (TSX.V: HTC) is celebrating news that a group of underwriters has agreed, subject to due diligence completion, to purchase 15 million units of combined common shares and warrants to purchase further common shares, which, upon closing will amount to an influx of C$15 million in aggregate gross proceeds (http://ibn.fm/KhNtT).

HTC is drawing on a wealth of experience in extraction, purification and distillation and aims to become one of Canada’s largest cannabidiol (CBD) extractors and refiners as it builds a strategy for processing hemp biomass under an infrastructure that will include: a 19,000-square-foot GMP Euro-compliant extraction tolling facility on six acres of land southeast of Regina, Saskatchewan, and a large‐scale extraction facility at a yet-to-be-determined location in the United States, according to a company news release published in June (http://ibn.fm/SM4S1).

Over time, the company has developed and optimized proprietary systems for biomass, gas and liquid extraction, as well as for the distillation of ethanol and ethanol-based solvents used in the extraction process, and those resources provide the backbone of the company’s products and services.

“HTC will continue to drive the business model, where HTC will own physical assets at our extraction and purification facilities while serving the clean energy and hemp biomass industries,” HTC Executive Chairman Lionel Kambeitz stated in the news release. “Our business model calls for both participating equity ownership and tolling revenue.”

In Canada, HTC has an agreement for the 2019 growing season through which it will receive a projected five million kilograms of hemp biomass for extracting CBD full spectrum oil, using Health Canada-approved cultivars. HTC will receive a percentage of the distillate as payment of the tolling fee. Another tolling agreement with a 60,000-acre farm is pending for the 2019, 2020, 2021 and beyond seasons.

The company’s management plans for a facility in the United States that will adapt the scalable production, extraction, purification and distillation techniques that it has developed in Canada. Leveraging their relationships with successful farming leaders, management will draw on standard operating procedures (SOPs) and best practices in genetics, fertility, crop protection and ingredient sales with multi‐year contracts. HTC then intends to pursue plans for two annual crop rotations producing new high-CBD genetic varieties. The company is also continually evaluating potential synergistic technologies that could use distillate chromatography, chemical isolation and molecular distillation for production benefits.

HTC also intends to leverage its relationship with its related entity, Purely Canada Foods, to provide sales and distribution for its Ingredient CBD market under the brands of Purely Canada Hemp, Purely Canada CBD, Purely Canada Cannabinoids and Purely Canada THC. Purely Canada Foods is expected to develop multi-year ingredient supply contracts with its existing and new global food, beverage and animal food industry customers.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• West Coast-based IONIC Brands has focused on vape products for recreational cannabis users, but a new agreement with a Washington-based partner grants it a foothold in the edibles and infused products sectors
• A second agreement between IONIC and an Australian Bluetooth technology producer will grant IONIC’s consumers access to vaporizer tech originally designed to help medical patients control the dosing of their medications
• The agreements mark an expansion of the cannabis holding company’s ability to provide secure dosing to recreational users
• IONIC expects to launch its newest vape product using the technology during the third quarter

Cannabis holding company IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is expanding its sphere of operations with agreements that enhance the vape manufacturer’s competitiveness in the edibles and infused products markets, as well as technological developments that are expected to provide IONIC’s recreational consumers an innovative experience.

The company announced July 24 that it has completed the previously announced acquisition of Washington-based Natural Extractions Inc., which is doing business as Zoots Premium Cannabis Infused Edibles (http://ibn.fm/fsurk).

Zoots is an edibles company whose product line includes drops, gummies, energy shots and hard candies manufactured to offer consistent and reliable dosing. The products are currently available at licensed recreational cannabis retailers in Illinois, Washington, Colorado and Massachusetts.

“Our top-rated Ionic vaporizer pen targets consumers interested in luxury cannabis products that can be discreetly consumed which make Zoots edibles a natural fit for our brand strategy,” IONIC Brands Chairman and CEO John Gorst stated in a news release. “The Zoots acquisition expands our market segments to the popular edibles space and expands our distribution network throughout the United States.”

Zoots was founded by brothers Dan, Michael and Patrick Devlin, and Dan will continue as the chief operating officer under the agreement. The company’s products feature cannabis oil from Zoots’ proprietary Cypress Extraction system and offer serving sizes as low as 5 mg tetrahydrocannabinol (THC), making it easy for consumers to manage dosage and control over the drug’s effect.

IONIC’s exclusive Heads of Agreement with Lifespot Health Limited (ASX: LSH) is also a significant step toward managing drug dosing (http://ibn.fm/8LVz5). Lifespot’s Bluetooth-enabled vaporizers were developed to help medical patients efficiently manage dosing of their prescriptions for chronic illnesses and unexpected medical conditions on their personal digital devices, including smartphones, tablets and desktop computers. The tech can also be used effectively for recreational cannabis consumption by IONIC’s customers, once the firms complete binding joint venture and distribution agreements.

Lifespot’s software works with enhanced sensor technology to provide self-learning algorithms that make the company’s products user-friendly and analytical.

“Smartphone Bluetooth technology is the future of cannabis delivery and dosing,” Gorst added. “The company is ecstatic to offer consumers advanced delivery technology that, before this agreement, was only available to medical patients. Ionic’s launch and distribution of the Slim-line Vape is expected to start in Q3 2019 in Washington, Oregon, Nevada and California. The Slim-line Vape is the first Bluetooth enabled vaporizer and platform designed specifically for the use of cannabis.”

The agreement also provides a framework for the ongoing development and improvement of cannabis vaporizer technologies for the recreational cannabis vaporizer market. IONIC has completed a purchase order for an initial series of vaporizer and software technologies, and the company plans to begin shipping the product line during the third quarter.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF

• Marijuana Company of America saw its second quarter profits jump 633.5 percent over the previous year
• Sales through its hempSMART brand continue to show strength, with more than $100,000 in gross sales reported for the month of July
• MCOA’s growing international presence is playing a key role in its profits as well, with 33.5 percent of the quarter’s revenue derived from sales in other countries
• The company recently redesigned its website in order to enhance the free flow of information between administration and company investors

Innovative hemp and cannabis product cultivator Marijuana Company of America Inc. (OTCQB: MCOA) is celebrating large gains reported through its second quarter statement, showing a year-over-year increase of 633.5 percent in revenue and a gross margin of 86 percent on $179,441 in profits.

“Our second quarter of 2019 has been our most successful quarter to date at hempSMART. We continue to generate strong sales and momentum in Q3 with over $100K in gross sales for just the month of July,” CEO Donald Steinberg stated in announcing the results (http://ibn.fm/Nv8lg).

Steinberg said that the company expects to see demand for its uniquely formulated hempSMART cannabidiol (CBD) products to remain constant during the coming quarters, allowing the company to expand the brand throughout the United States and into Europe.

MCOA announced this summer that it had successfully introduced its products in Scotland and the Netherlands, selling out the items that company representatives had taken for the launch of its botanicals in those countries and enlisting new marketing associates (http://ibn.fm/EZQgN).

Total hempSMART revenues reached $208,580 for the quarter ended June 30, marking a significant increase from the $28,435 reported a year earlier. International sales made up 33.5 percent of the quarterly revenue. Gross sales for the first six months of the year were $323,390, with a $254,373 gross margin, as compared to $47,455 in sales and a $32,835 gross margin during the same period a year earlier.

The company’s net loss plummeted from $7.6 million to $419,624 for the quarter, as well.

MCOA recently announced that it has redesigned its website as part of its bid to increase transparency and clarity in its communications with investors (http://ibn.fm/gzMyC). The site will provide key information on the company’s portfolio of brands, farming projects, financial data, management, regulatory compliance and more.

“The new website presents a fresh design with enhanced functions focused on the company’s unique market position and its most recent developments that will be of value to current and prospective shareholders,” Steinberg added.

Marijuana Company of America’s key areas of focus are on the research and development of legal hemp-based consumer products, building an affiliate marketing program to promote its CBD products, leasing real property to separate business entities for the growth and sale of cannabis and expansion into ancillary areas of the legalized cannabis and hemp industry as opportunities develop.

For more information, visit the company’s websites at www.MarijuanaCompanyofAmerica.com and www.hempSMART.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• HTC announced entering into a letter agreement for a CAD$15 million bought deal private placement of units led by Canaccord Genuity Corp. on July 3, 2019 (subject to closing);
• HTC’s business model includes owning physical assets at extraction and purification facilities to serve the clean energy and hemp biomass industries;
• Hemp biomass tolling contracts with producers and hemp biomass providers are either signed or being negotiated in Canada and the U.S.;
• HTC will provide “local to grower” drying-to-biomass storage capability and transportation of dried biomass to HTC extraction facilities;
• HTC is constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility near Regina, Saskatchewan; and
• HTC has developed and optimized proprietary extraction and purification systems for biomass, gas and liquid extraction.

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

• LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
• PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
• Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

• Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
• Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
• Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC